Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Return on Equity (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Return on Equity for 7 consecutive years, with 0.27% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity fell 10.0% to 0.27% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.27%, a 10.0% decrease, with the full-year FY2025 number at 0.25%, down 21.0% from a year prior.
  • Return on Equity was 0.27% for Q4 2025 at Fulcrum Therapeutics, up from 0.34% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.1% in Q2 2023 to a low of 0.62% in Q1 2021.
  • A 5-year average of 0.31% and a median of 0.26% in 2023 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: soared 50bps in 2023, then fell -24bps in 2025.
  • Fulcrum Therapeutics' Return on Equity stood at 0.37% in 2021, then grew by 22bps to 0.29% in 2022, then increased by 26bps to 0.21% in 2023, then grew by 18bps to 0.17% in 2024, then tumbled by -58bps to 0.27% in 2025.
  • Per Business Quant, the three most recent readings for FULC's Return on Equity are 0.27% (Q4 2025), 0.34% (Q3 2025), and 0.23% (Q2 2025).